Anti-Thyroid Peroxidase Antibody in Vitiligo: A Prevalence Study

Table 2

Sample characteristics of study participants according to anti-TPO Ab status.

		Anti-TPO Ab status
Sl. number	Characteristic variable	Positive	Negative	value
		(>35 IU/mL)	(<35 IU/mL)
1	Number of participants	28	72	—
2	Number of male, female participants	8, 20	33, 39	0.115
3	Age^#	34.50 ± 13.99	27.54 ± 15.02	0.037^*
4	Reported age at onset of vitiligo	24.59 ± 15.46	24.88 ± 15.83	0.982
5	Duration since first lesion of vitiligo	5.19 ± 6.63	4.42 ± 5.85	0.700
6	Positive history of vitiligo in family (%)	10.71	13.89	1.000
7	Positive history of precipitating factors (%)	17.86	4.17	0.037^*
8	Stable vitiligo [VIDA Score ≤ 0]	3.57	19.44	0.222
9	Vitiligo type (segmental) (%)	3.57	4.17	1.000
10	VASI <1.00 (%)	32.14	18.06	0.376
11	Vitiligo variants (quadrichrome and trichrome) (%)	17.86	9.72	0.308
12	Koebner’s phenomenon present (%)	10.71	2.78	0.132
13	Leukotrichia present (%)	14.29	13.89	1.000
14	Associated dermatological disorders (%)	7.14	04.17	0.617
15	Associated systemic disorder (%)	0	5.56	0.574
16	Associated nonthyroid autoimmune disorder (%)	7.14	0	0.076
17	Serum TSH titres (μIU/mL)	11.31 ± 41.03	2.67 ± 2.27	0.514
18	Euthyroid (%)	75.00	87.50	0.139

Mean ± standard deviation; median in years.
Statistically significant ( < 0.05).